How Can Targeting Signaling Pathways Help in Cancer Treatment?
Targeting dysregulated signaling pathways offers a strategic approach to cancer treatment. Targeted therapies are designed to specifically inhibit molecules involved in these pathways. For instance, tyrosine kinase inhibitors like imatinib are used to treat chronic myeloid leukemia by blocking the BCR-ABL fusion protein. Similarly, mTOR inhibitors like everolimus are used to target the PI3K/Akt/mTOR pathway in certain cancers.
